1 / 9

Efficacy of anti-inflammatory SI g As after topical treatment in inflammatory bowel disease

Efficacy of anti-inflammatory SI g As after topical treatment in inflammatory bowel disease. DISCLOSURE R. Arends 1, , R. Ubink 1 , M. van der Lee 1 , G. de Roo 2 , L. Dickey 3 , G. Rouwendal 4 , G. Ariaans 4 , W. Dokter 1 1 Preclinical Department, 2 Bio DSP, 3 LEX Platform

elpida
Download Presentation

Efficacy of anti-inflammatory SI g As after topical treatment in inflammatory bowel disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Efficacy of anti-inflammatory SIgAs after topical treatment in inflammatory bowel disease • DISCLOSURE • R. Arends1,, R. Ubink1, M. van der Lee1, G. de Roo2, • L. Dickey3, G. Rouwendal4, G. Ariaans4, W. Dokter1 • 1Preclinical Department, 2Bio DSP, 3LEX Platform • 4New Molecular Entities, Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands • B. Weigmann, M. Neurath • Department of Gastroenterology, Pneumology and Endocrinology of the MedizinischeKlinik 1, Erlangen, Germany • B. Corthésy • Centre HospitalierUniversitaireVaudois, R & D Laboratory of the Division of Immunology and Allergy, Lausanne, Switzerland

  2. Introduction SECRETORY-iga (SIgA) SIgA produced in Lemna minor effectively binds human and mouse TNFα (Patent application WO2013/087912 ) 2

  3. uptake of SIgA in polarized Caco-2 cells Cy5 labeled SIgA in green ZonaOccludens (ZO-1) in red, Nuclei (DAPI) in blue Apical uptake of SIgA by polarized Caco-2 cells 3

  4. BIO-IMAGING OF ORALLY ADMINISTERED SIgA SIgA molecule ends up in gut, 24h after oral treatment 4

  5. Localization of sIgA in distal colon after topical administration Lumen SC-20656 ULEX-1DAPI Lumen SC-20656 EpCAMDAPI Sc-20656 (human secretory chain) in red, DAPI (Nuclei) in blue LEFT ULEX-1 (Lectin) in green RIGHTEpCAM (Epithelial cell adhesion molecule) in green SIgA localized in epithelial cells in distal colon after oral and rectal administration 5

  6. Biodistribution (Qwba) SIgA iV and PO Intravenous Oral SIgA rapidly cleared from circulation after IV administration t1/2 ~2h Very low systemic exposure after oral administration 6

  7. SIgA in TNBS-INDUCED IBD model in mice SIgA inhibits TNBS-induced IBD after Oral and Rectal administration

  8. Summary and conclusion • We have successfully generated a monoclonal anti-TNFα secretory IgA antibody in duckweed. • Anti-TNFα SIgA is a promising molecule for topical treatment of IBD, combining elimination of adverse effects associated with systemic exposure with the convenience of topical treatment.

  9. SIgAs the future for topical IBD treatment!

More Related